Pfenex to Participate in the William Blair Growth Stock Conference
Pfenex Inc. (NYSE American: PFNX) will have its CEO, Eef Schimmelpennink, participate in a virtual fireside chat at the William Blair Growth Stock Conference on June 9, 2020, from 9:20 am to 9:50 am Central Time. The event can be accessed through this link. Pfenex focuses on developing protein therapies using its proprietary Pfenex Expression Technology, with PF708 approved for osteoporosis treatment in the U.S. The company is also advancing other therapies in collaboration with Jazz Pharmaceuticals.
- None.
- None.
SAN DIEGO, June 05, 2020 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that Eef Schimmelpennink, President and Chief Executive Officer, will participate in a fire side chat at the William Blair Growth Stock Conference on June 9, 2020. The discussion will be virtual and accessible at http://www.wsw.com/webcast/blair56/pfnx.
| Presentation Details: | |
| 10%; width: | 90%; width: |
| Time: | 9:20 am – 9:50 am Central Time (7:20 am – 7:50 am Pacific Time) |
| Link: | http://www.wsw.com/webcast/blair56/pfnx |
Interested parties can access the live audio webcast and archive from the Investors Section of Pfenex's website at www.pfenex.com.
About Pfenex Inc.
Pfenex is a development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to develop and improve protein therapies for unmet patient needs. Using the patented Pfenex Expression Technology platform, Pfenex has created an advanced pipeline of potential therapeutic equivalents, and vaccines. Pfenex’s lead product candidate is PF708, a therapeutic equivalent candidate to Forteo® (teriparatide injection). PF708 has been approved in the U.S. for the treatment of osteoporosis in certain patients at high risk for fracture, and marketing authorization applications are pending in other jurisdictions. In addition, Pfenex is developing hematology/oncology products in collaboration with Jazz Pharmaceuticals, including PF743, a recombinant crisantaspase, and PF745, a recombinant crisantaspase with half-life extension technology. Pfenex also uses its Pfenex Expression Technology platform to produce CRM197, a diphtheria toxoid carrier protein used in prophylactic and therapeutic vaccines.
Pfenex investors and others should note that Pfenex announces material information to the public about Pfenex through a variety of means, including its website (http://www.pfenex.com/), its investor relations website (http://pfenex.investorroom.com/), press releases, SEC filings, public conference calls, corporate Twitter account (https://twitter.com/pfenex), Facebook page (https://www.facebook.com/Pfenex-Inc-105908276167776/timeline/), and LinkedIn page (https://www.linkedin.com/company/pfenex-inc) in order to achieve broad, non-exclusionary distribution of information to the public and to comply with its disclosure obligations under Regulation FD. Pfenex encourages its investors and others to monitor and review the information Pfenex makes public in these locations as such information could be deemed to be material information. Please note that this list may be updated from time to time.
Company Contact:
investorrelations@pfenex.com
FAQ
What is the date of Pfenex's participation in the William Blair Growth Stock Conference?
Who from Pfenex will be speaking at the conference?
What time will Pfenex's presentation occur at the conference?
How can I access the Pfenex conference webcast?
What is PF708 and its current status?
